Richtlijn: Niet-kleincellig longcarcinoom (2.0) - Kwaliteitskoepel

Richtlijn: Niet-kleincellig longcarcinoom (2.0)397 - Noue ANoue A, Kobayashi K, Usui K, Maemondo M, et al. First-line gefitinib for patiënts with advancedNon–Small-Cell Lung Cancer harboring epidermal growth factor receptor mutations without indication forchemotherapy. J Clin Oncol 27:1394-1400, 2009.398 - NSCLC Collaborative GroupNSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updateddata on individual patiënts from 52 randomised clinical trials. BMJ 311:899-909, 1995.400 - NSCLC Meta-Analyses Collaborate GroupNSCLC Meta-Analyses Collaborate Group. Chemotherapy in addition to supportive care improves survivalin advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patiënt datafrom 16 randomized controlled trials. J Clin Oncol 26:4617-4625, 2008.401 - NSCLC Meta-analyses Collaborative GroupNSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH,Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF,Tribodet H, van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, inoperable non-small-cell lung cancer: two meta-analyses of individual patiënt data. Lancet 375:1267-1277,2010.402 - Nyman JNyman J, Johansson KA, Hultén U. Stereotactic hypofractionated radiotherapy for stage I non-small celllung cancer--mature results for medically inoperable patiënts. Lung Cancer 51:97-103, 2006.403 - O`Rourke NO`Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R CollRadiol) 12:141-144., 2000.404 - Ohkubo TOhkubo T, Okayasu T, Hashimoto M, Shiiya N, Konishi K, Motohara T, et al. [Surgery for intrathoracicrecurrence of non-small cell lung cancer]. Kyobu Geka 53:127-131, 2000.405 - Ohno YOhno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, Yoshikawa T, Matsumoto S, Kotani Y, Sugimura K.Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-bodydiffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008 248:643-654, 2008.406 - Okada MOkada M, Sakamoto T, Nishio W, Uchino K, Tsuboshima K, Tsubota N. Pleural lavage cytology innon-small cell lung cancer: Lessons from 1000 consecutive resections. J Thorac Cardiovasc Surg126:1911-1915, 2003.407 - Okada MOkada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. How should interlobar pleural invasion beclassified? Prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg 68:2049-2052, 1999.408 - Okada MOkada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for reasonable mediastinal lymphadenectomy inbronchogenic carcinomas: role of subcarinal nodes in selective dissection. J Thorac Cardiovasc Surg116:949-953, 1998.409 - Okada MOkada M, Yamagishi H, Satake S, Matsuoka H, Miyamoto Y, Yoshimura M, et al. Survival related to lymphnode involvement in lung cancer after ‘sleeve’-lobectomy compared with pneumonectomy. J ThoracCardiovasc Surg 119:814-819, 2000.410 - Okamoto IOkamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsivesmall-cell lung cancer. Ann Oncol 17:1028-1029, 2006.06/09/2011 Niet-kleincellig longcarcinoom (2.0) 123